Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib
| العنوان: | Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib |
|---|---|
| المؤلفون: | Antonello Gibbin, Jessica Howell, C. Ferrari, James R M Black, Tadaaki Arizumi, Michela Emma Burlone, Masatoshi Kudo, David J. Pinato, Pierluigi Toniutto, Laura Sellers, G. Guaschino, Mario Pirisi, Ramya Ramaswami, Rohini Sharma |
| المصدر: | Scopus-Elsevier Oncotarget |
| بيانات النشر: | Impact Journals, LLC, 2017. |
| سنة النشر: | 2017 |
| مصطلحات موضوعية: | Male, CLIP score, IMPACT, Neutrophils, PREDICT, 0302 clinical medicine, BCLC, Inflammation, Liver cancer, VEGF inhibitor, Lymphocytes, CIRRHOSIS, OUTCOMES, Liver Neoplasms, Middle Aged, Sorafenib, Prognosis, C-REACTIVE PROTEIN, SINGLE-CENTER EXPERIENCE, Oncology, 030220 oncology & carcinogenesis, Hepatocellular carcinoma, Female, 030211 gastroenterology & hepatology, LYMPHOCYTE RATIO, Life Sciences & Biomedicine, Research Paper, medicine.drug, Niacinamide, Risk, medicine.medical_specialty, Carcinoma, Hepatocellular, Antineoplastic Agents, CELL DISTRIBUTION WIDTH, liver cancer, 03 medical and health sciences, Predictive Value of Tests, Internal medicine, SCORE, medicine, Humans, SKIN TOXICITY, Neutrophil to lymphocyte ratio, Aged, Neoplasm Staging, Retrospective Studies, Science & Technology, business.industry, Phenylurea Compounds, Cancer, Red blood cell distribution width, Cell Biology, Hepatology, medicine.disease, Survival Analysis, BCLC Stage, Surgery, business, Biomarkers, Follow-Up Studies |
| الوصف: | // Jessica A. Howell 1, 2, 3, * , David J. Pinato 1, * , Ramya Ramaswami 1 , Tadaaki Arizumi 4 , Carlotta Ferrari 5 , Antonello Gibbin 5 , Michela E. Burlone 5 , Giulia Guaschino 5 , Pierluigi Toniutto 6 , James Black 1 , Laura Sellers 1 , Masatoshi Kudo 4 , Mario Pirisi 5 and Rohini Sharma 1 1 Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK 2 Centre for Population Health, Burnet Institute, Melbourne, Australia 3 Department of Medicine, University of Melbourne, Melbourne, Australia 4 Department of Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka-Sayama, Osaka, Japan 5 Department of Translational Medicine, Universita degli Studi del Piemonte Orientale “A. Avogadro”, Novara, Italy 6 Department of Experimental and Clinical Medicine, University of Udine, Udine, Italy * These authors have contributed equally to the work Correspondence to: Jessica A. Howell, email: jessica.howell@svha.org.au Keywords: liver cancer, VEGF inhibitor, CLIP score, BCLC, inflammation Received: March 30, 2016 Accepted: October 13, 2016 Published: February 14, 2017 ABSTRACT Background and Aims: Response to sorafenib is highly variable in hepatocellular carcinoma (HCC). Baseline inflammatory parameters and treatment toxicities may improve survival prediction in patients on sorafenib therapy. Results: 442 patients with advanced stage HCC on sorafenib were recruited (follow-up 5096 person-months at risk). 88% had BCLC stage B or greater HCC and 72.3% had Child-Pugh A cirrhosis. On Cox multivariate regression, previously-treated HCC (HR 0.579, 95% CI 0.385-0.872, p=0.009), Cancer of Liver Italian Program (CLIP) score (HR 1.723, 95% CI 1.462-2.047, p |
| تدمد: | 1949-2553 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53950e6492290a4263e0a55a0c9165fe https://doi.org/10.18632/oncotarget.15322 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....53950e6492290a4263e0a55a0c9165fe |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 19492553 |
|---|